In recent years, with the introduction of immune checkpoint inhibitors (ICIs), such as programmed cell death-1 (PD-1) and programmed cell death-ligand 1 (PD-L1) antibodies, the outcomes of metastatic non-small cell lung cancer (NSCLC) have greatly improved (2–4). The gene discussed is CD274; the disease is non-small cell lung carcinoma.